Navigation Links
NeoTract Designates Dr. Michael Verni as UroLift® Center of Excellence
Date:3/11/2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Michael Verni, MD, Urology Center in Las Vegas, NV, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Verni has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.    

“Dr. Michael Verni has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations

Media:
Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction
1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016
MAC00968-01 Rev A

Read the full story at https://www.prweb.com/releases/neotract_designates_dr_michael_verni_as_urolift_center_of_excellence/prweb16973906.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. NeoTract Designates Dr. John Kefer as UroLift® Center of Excellence
2. NeoTract Designates Dr. Aaron Berger as UroLift® Center of Excellence
3. NeoTract Designates Dr. Garrett Matsunaga as UroLift® Center of Excellence
4. NeoTract Designates Dr. Bradley Wilson as UroLift® Center of Excellence
5. NeoTract Designates Dr. Ian M. Stormont as UroLift® Center of Excellence
6. NeoTract Designates Dr. Ryan Chartrand as UroLift® Center of Excellence
7. NeoTract Designates Pankaj M. Jain as UroLift® Center of Excellence
8. NeoTract Designates Dr. Jaspreet Parihar as UroLift® Center of Excellence
9. San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June
10. The White House Designates Mercy College a Bright Spot in Hispanic Education
11. United Benefit Advisors Designates Valued Pharmacy Services as Strategic Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... June 26, 2020 , ... ... is to provide high-quality, intensive education and training that prepares graduates for professional ... as new member of the Board of Trustees. , Ms. Williams currently serves ...
(Date:6/28/2020)... , ... June 26, 2020 , ... ... essential workers and the general public. As a supplier of top-quality masks, sanitizers ... direct source for PPE equipment. President Priya Agarwal observed, “All of our masks ...
(Date:6/28/2020)... ... , ... World Allergy Organization (WAO), serving its membership of ... to July 4, 2020, to the importance of continued allergy self-care during the ... is a disease spreading around the world caused by infection with a new ...
(Date:6/24/2020)... NEWPORT BEACH, Calif. (PRWEB) , ... June 24, 2020 , ... ... that it has launched a new website at http://www.evolvednaturals.com The newly launched ... assortment of broad-spectrum CBD oils , and a comprehensive line of skincare ...
(Date:6/24/2020)... ... June 24, 2020 , ... SPH Analytics , ... Physician Hospital Organization (PHO) has successfully deployed SPH’s Population Care™ all-payer population health ... value-based care. Use of Population Care is benefitting more than 77,000 patients covered ...
Breaking Medicine News(10 mins):
(Date:6/19/2020)... Mo. (PRWEB) , ... June 19, 2020 , ... ... end hunger in individuals diagnosed with food allergies and celiac disease announced the first ... Allergy. , This webinar is scheduled for Friday, June 19, 2020, from 11:00, ...
(Date:6/19/2020)... , ... June 19, 2020 ... ... of its cross-platform campaign 'Clinical Trials.' This campaign showcases the innovative medical ... these studies, thereby advancing knowledge and disease treatment. This public awareness campaign ...
(Date:6/19/2020)... , ... June 18, 2020 , ... World Allergy Organization ... emphasize the importance of maintaining regular care of allergies and asthma during the COVID-19 ... world caused by infection with a new strain of coronavirus (SARS-CoV-2). Patients with symptoms ...
Breaking Medicine Technology: